Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas
- Author:
Jun Ho YI
1
Author Information
- Publication Type:REVIEW ARTICLE
- From:Blood Research 2021;56(S1):S1-S4
- CountryRepublic of Korea
- Language:English
- Abstract: Despite substantially improved survival with rituximab-based treatment regimens, there is an unmet medical need for better treatments of B-cell lymphoma, particularly for patients with relapsed or refractory disease. Retreatment with rituximab exerts a limited effect in these patients, and platinum-based salvage treatment followed by autologous stem cell transplantation remains the only curative option. Recent strategies have focused on targeting novel B-cell surface markers, inhibiting B-cell receptor signaling, and enhancing the cytotoxicity of effector cells. The current article will review the recent progress in immunochemotherapy targeting other than CD20 for B-cell lymphomas.
